ABSTRACT
The brain-blood partition coefficient (log BB) is a determining factor for the efficacy of central nervous system acting drugs. Since large-scale experimental determination of log BB is unfeasible, alternative evaluation methods based on theoretical models are desirable. Toward this direction, we propose a model that correlates log BB with physically significant descriptors for 76 structurally diverse molecules. We employ Monte Carlo simulations of the compounds in water to calculate such properties as the solvent-accessible surface area (SASA), the number of hydrogen bond donors and acceptors, the solute dipole, and the hydrophilic, hydrophobic and amphiphilic components of SASA. The physically significant descriptors are identified and a quantitative structure-prediction relationship is constructed that predicts log BB. This work demonstrates that computer simulations can be employed in a semi-empirical framework to build predictive QSPRs that shed light on the physical mechanism of biomolecular phenomena.
Subject(s)
Blood-Brain Barrier/physiology , Models, Biological , Animals , Computer Simulation , Drug Design , Humans , Hydrogen Bonding , In Vitro Techniques , Monte Carlo Method , Quantitative Structure-Activity Relationship , Solvents , Thermodynamics , WaterABSTRACT
A series of esters of 1,4-disubstituted tetrahydropyridine carboxylic acids (I) has been synthesized and characterized as potential m1 selective muscarinic receptor antagonists. The affinity of these compounds for the five human muscarinic receptor subtypes (Hm1-Hm5) was determined by the displacement of [3H]-NMS binding using membranes from transfected Chinese hamster ovarian cells. One of the most potent and selective compounds of this series is an analogue of I [11, R1 = (CH2)5CH3], which has an IC50 value of 27.3 nM at the m1 receptor and possesses 100-fold (m2), 48-fold (m3), 74-fold (m4), and 19-fold (m5) selectivities at the other receptors. Thus, this analogue appears to be more selective on the basis of binding than the prototypical m1 antagonist, pirenzepine. Functional data, such as the inhibition of carbachol-stimulated phosphatidylinositol hydrolysis, on selected analogues confirmed the muscarinic antagonistic properties of this chemical series.
Subject(s)
Muscarinic Antagonists/chemistry , Animals , CHO Cells , Cricetinae , Humans , Magnetic Resonance Spectroscopy , Mass Spectrometry , Molecular Structure , Muscarinic Antagonists/classification , Muscarinic Antagonists/pharmacology , Structure-Activity RelationshipABSTRACT
VisualiSAR is a program designed to display chemical structures, find similarities and differences between them, and highlight relationships that might exist. The program integrates cluster analysis for the grouping of structurally related compounds, modal analysis of molecular fingerprints for the sorting and highlighting of chemical features, and a Web-based interface for flexibility and ease of use. VisualiSAR has proved useful for a number of applications including the discernment of structure-activity relationships (SAR) of high-volume screening data, and general structure browsing. This article discusses the design of the tool and illustrates two applications.
Subject(s)
Computer Simulation , Internet , Organic Chemicals/chemistry , Software , Structure-Activity Relationship , Models, Molecular , Molecular ConformationABSTRACT
PURPOSE: The feasibility of using hydrophobicity measurements as screens for intracellular availability in T-cells or intestinal permeability in Caco-2 cells was examined. METHODS: T-cell experiments: Cells were counted, collected, then incubated with drug solution at 37 degrees C. At selected time intervals, uptake was quenched by transferring a sample into oil, followed by rinsing, lysis of cells, protein precipitation and analysis by HPLC. Caco-2 cell experiments: Cells were grown on plastic dishes for 7-10 d, then rinsed and incubated with drug solution at 37 degrees C. Uptake was quenched, cells were lysed, protein precipitated and drug was analyzed by HPLC. IAM chromatography: Stock solutions were injected onto an IAM column for HPLC. Mobile phase consisted of varying amounts of acetonitrile in buffer (pH 7.4). The capacity factor, k'IAM, was calculated using citric acid to measure the void volume and was obtained by extrapolation to pure buffer. RESULTS: Nine HIV protease inhibitors were studied for uptake by CEM T-cell suspensions or Caco-2 cell monolayers. Capacity factors (log) between IAM and C-18 columns were positively correlated for this series. Caco-2 uptake rates correlated well with T-cell uptake rates when normalized by protein mass. Single-variable regression using IAM or C-18 columns was acceptable for analysis of T-cell data. Correlation coefficients between T-cell uptake and log k'IAM or log k'C-18 were not improved with multivariable regression. Correlation between Caco-2 uptake and log k'IAM was enhanced when molecular weight and hydrogen-bonding potential were included in multivariable regression analysis (from r2 of 0.39 to 0.91). Correlations obtained using log k'IAM, log k'C-18 or log distribution coefficient (log D) were comparable when regressed against Caco-2 uptake using this approach. Calculated log partition coefficient (ClogP) provided the poorest correlation in the multivariable analysis (r2=0.57 for T-cell uptake and r2=0.71 for Caco-2 cell uptake). CONCLUSIONS: Uptake of HIV protease inhibitors by T-cell suspensions or Caco-2 cell monolayers was positively correlated. Uptake by T-cell suspensions was adequately described by hydrophobicity alone. Description of uptake by Caco-2 cell monolayers required multivariable regression analysis in which molecular weight and hydrogen bonding were included. Experimental measures of hydrophobicity (log k'IAM, log k'C-18 and log D) were superior to ClogP in the correlation analysis.
Subject(s)
CD4-Positive T-Lymphocytes/metabolism , HIV Protease Inhibitors/pharmacokinetics , Membranes, Artificial , Biological Transport , Caco-2 Cells , Cells, Cultured , Chromatography , Feasibility Studies , Humans , Models, Biological , WaterABSTRACT
A series of diaryl-substituted heterocyclic ureas was prepared, and their ability to inhibit acyl-CoA: cholesterol O-acyltransferase (ACAT) in vitro and to lower plasma total cholesterol in cholesterol-fed animal models in vivo was examined. N-(2,6-Diisopropylphenyl)-N'-tetrazole or isoxazole-substituted heterocyclic ureas proved optimal. A carbon chain of 11-14 carbons substituted 1,3 with respect to the amine provided the optimal side chain. Substitution of the alkyl chain generally lowered activity. Tetrazole urea 2i dosed at 3 mg/kg lowered plasma total cholesterol (TC) 67% in an acute, cholesterol-fed (C-fed) rat model of hypercholesterolemia and 47% in C-fed dogs. Tetrazole 2i, dosed at 10 mg/kg, also lowered TC 52% and raised HDL cholesterol 113% in rats with pre-established hypercholesterolemia.
Subject(s)
Anticholesteremic Agents/chemistry , Sterol O-Acyltransferase/antagonists & inhibitors , Urea/analogs & derivatives , Animals , Cholesterol, HDL/blood , Chromatography, High Pressure Liquid , Disease Models, Animal , Dogs , Female , Hypercholesterolemia/drug therapy , Male , Rats , Tetrazoles/chemistryABSTRACT
An algorithm, Stigmata, is described, which extracts structural commonalities from chemical datasets. It is discussed using several illustrative examples and a pharmaceutically interesting set of dopamine D2 agonists. The commonalities are determined using two-dimensional topological chemical descriptions and are incorporated into the key feature of the algorithm, the modal fingerprint. Flexibility is built into the algorithm by means of a user-defined threshold value, which affects the information content of the modal fingerprint. The use of the modal fingerprint as a diversity assessment tool, as a database similarity query, and as a basis for color mapping the determined commonalities back onto the chemical structures is demonstrated.
Subject(s)
Algorithms , Databases, Factual , Pharmaceutical Preparations/chemistry , Dopamine Agonists/chemistry , Indoles/chemistry , Ligands , Molecular Structure , Phenols/chemistry , Piperazine , Piperazines/chemistryABSTRACT
A series of radiolabeled compounds related to renin inhibitor structures was synthesized to represent a range of physicochemical properties. These compounds were tested in assays for intestinal absorption and hepatic clearance in order to define parameters conducive to optimizing bioavailability. In general, compounds with higher lipophilicity were better absorbed from the intestine. Absorption may also be dependent on molecular charge, as compounds with ionizable functionality were less well-absorbed than neutral compounds. Neutral compounds showed some dependency on molecular weight, with smaller compounds exhibiting better absorption. While uptake into hepatic cells was rapid regardless of partition coefficient or molecular weight, rate of appearance in bile was dependent on the molecular weight of the compounds.
Subject(s)
Protease Inhibitors/pharmacokinetics , Renin/antagonists & inhibitors , Administration, Oral , Animals , Biological Availability , Intestinal Absorption , Liver/metabolism , Male , Protease Inhibitors/administration & dosage , Protease Inhibitors/chemistry , Rats , Rats, Wistar , Structure-Activity RelationshipABSTRACT
To examine the effects of bioisosteric replacement on the biological activity of our previously disclosed disubstituted urea inhibitors of the enzyme acyl-CoA:cholesterol acyltransferase (ACAT), we prepared a series of N'-substituted and N',N'-disubstituted glycine anilides. These compounds were tested for the ability to inhibit ACAT in vitro and lower plasma total cholesterol in cholesterol-fed rats given a single high-fat, high-cholesterol meal. ACAT inhibitory potency was greatest in compounds containing 2,6-diisopropyl substituents in the anilide portion with the glycine nitrogen substituted by a 1,1-diphenylmethyl moiety. Small improvements in potency in vitro were obtained by substitution of electron donating groups in the 2-, 3- or 5-positions of the aryl rings of the 1,1-diphenylmethyl moiety, but not by substitution in the 4-position. In vitro potency was maintained, but not improved by acylation of the glycine nitrogen. Through a QSAR analysis of in vitro ACAT inhibition for this set of compounds, an equation could be derived which accounted for 85% of the variance in the dataset. An optimal clogp of 6.65 was found, comparable to that found for other series of ACAT inhibitors. In general, compounds from this series displayed inhibitory potency against ACAT in vitro and hypocholesterolemic activity in the in vivo rat model of hypercholesterolemia comparable to that found with the ureas.
Subject(s)
Anilides/chemistry , Anticholesteremic Agents/chemistry , Glycine/chemistry , Sterol O-Acyltransferase/antagonists & inhibitors , Acyl Coenzyme A/drug effects , Anilides/chemical synthesis , Anilides/pharmacology , Animals , Anticholesteremic Agents/pharmacology , Drug Design , Glycine/pharmacology , In Vitro Techniques , Intestinal Mucosa/metabolism , Male , Microsomes/metabolism , Rabbits , Rats , Rats, Sprague-Dawley , Structure-Activity RelationshipABSTRACT
The presence of plasma cholesteryl ester transfer protein (CETP) activity may be atherogenic, and, therefore, strategies to inhibit its activity or production may result in a beneficial effect on lipoprotein profiles and the disease process. The current report describes 4-phenyl-5-tridecyl-4H-1,2,4- triazole-3-thiol (PD 140195), a novel CETP inhibitor. The concentration-dependent inhibition of CETP by PD 140195 and the inhibitory monoclonal antibody (Mab) TP2 is demonstrated in a variety of in vitro assay systems. Molecular models of PD 140195 suggest a spatial mimicry of the cholesteryl ester structure. Despite the structural similarity, kinetic studies with a fluorescent cholesteryl ester analog suggest that the inhibition of transfer is not competitive. PD 140195 also selectively inhibited cholesteryl ester but not triglyceride transfer, while the Mab TP2 blocked CETP transfer of both. Studies were carried out to determine whether CETP inhibition observed in vitro could also be demonstrated in vivo. When PD 140195 was intravenously infused to anesthetized rabbits (up to 20 mg/kg), only transient CETP inhibition was observed. In vitro reconstitution studies in the presence of bovine serum albumin resulted in marked reduction of PD 140195 inhibitory activity. Thus, the low activity of PD 140195 in whole plasma probably results from binding to other plasma proteins.
Subject(s)
Anticholesteremic Agents/isolation & purification , Carrier Proteins/antagonists & inhibitors , Glycoproteins , Triazoles/pharmacology , Animals , Anticholesteremic Agents/metabolism , Cholesterol Ester Transfer Proteins , Cholesterol Esters/chemistry , Cholesterol Esters/metabolism , Humans , Models, Molecular , Rabbits , Triazoles/metabolism , Triglycerides/metabolismABSTRACT
A series of disubstituted ureas containing amide or amine groups was prepared and evaluated for their ability to inhibit acyl-CoA:cholesterol O-acyl transferase in vitro and to lower plasma total cholesterol in a variety of cholesterol-fed rat models in vivo. The presence of polar or ionizable functionalities within this class of compounds may impart greater aqueous solubility to those compounds and thus allow improved transport to the enzyme location within the intestinal enterocyte. Compounds from this class exhibit good cholesterol lowering in a chronic cholesterol-fed rat model of hypercholesterolemia even when dosed in an aqueous vehicle. In general, the amine-containing compounds were more potent and efficacious than the amides in the acute rat model of hypercholesterolemia. Further structure-activity relationship studies showed that the preferred position of the amide/amine group was beta to the urea moiety and not alpha, and that in this series, the presence of a secondary amine (or amide) proton is required for good in vitro potency. One of these compounds, 9n(-), lowered plasma total cholesterol (-47%) and elevated high-density lipoprotein cholesterol (+256%) when dosed in an aqueous vehicle to rats with preestablished hypercholesterolemia.
Subject(s)
Amides/chemistry , Amines/chemistry , Anticholesteremic Agents/chemistry , Carbamates/chemistry , Sterol O-Acyltransferase/antagonists & inhibitors , Urea/chemistry , Animals , Anticholesteremic Agents/pharmacology , Disease Models, Animal , Rabbits , Rats , Structure-Activity RelationshipABSTRACT
We have synthesized a series of N-phenyl-N'-aralkyl and N-phenyl-N'-(1-phenylcycloalkyl)ureas as inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). This intracellular enzyme is thought to be responsible for the esterification of dietary cholesterol; hence inhibition of this enzyme could reduce diet-induced hypercholesterolemia. For this series of compounds, the in vitro ACAT inhibitory activity was improved by increasing the bulk of the 2,6-substituents on the phenyl ring. Additionally, we found that spacing of the aromatic rings was critical for ACAT inhibitory activity. A phenyl ring five atoms away from the requisite 2,6-diisopropylphenyl moiety was optimal for in vitro activity. Substitution alpha to the N'-phenyl moiety enhanced in vitro potency. In the case of phenylcycloalkyl ureas, ACAT inhibitory activity was independent of the size of the cycloalkyl ring. From this series of analogs, compound 25, which had excellent in vitro potency for inhibiting ACAT, was found to lower plasma cholesterol by 73% in vivo when administered in the diet at 50 mg/kg in an animal model of hypercholesterolemia. In this model, compound 25 lowered plasma cholesterol dose dependently and was as efficacious as the Lederle ACAT inhibitor CL 277082.
Subject(s)
Anticholesteremic Agents/chemical synthesis , Anticholesteremic Agents/pharmacology , Sterol O-Acyltransferase/antagonists & inhibitors , Urea/analogs & derivatives , Carbanilides/chemical synthesis , Carbanilides/pharmacology , Structure-Activity Relationship , Urea/pharmacologyABSTRACT
A study of structure-activity relationships of substituted beta-ketoamide ACAT inhibitors I and II was performed. The results of this study suggest that whereas the beta-keto group was tolerated with no loss in activity, beta-hydroxy and oxime moieties led to significantly reduced activity in vitro and in vivo. The most potent inhibitor from the acyclic series (I) (11, IC50 = 0.006 microM) contained a C-13 alkyl chain. This compound reduced plasma total cholesterol by 38% and 66% at 3 and 30 mg/kg, respectively, in cholesterol-fed rats. Dimethylation alpha to the anilide core (5) and subsequent N-methylation of the amide NH (6) decreased in vitro potency significantly. It was also found that high potency was retained with inhibitors which incorporated the carbonyl into a lactam ring (II).
Subject(s)
Anilides/chemistry , Anilides/pharmacology , Anticholesteremic Agents/chemistry , Anticholesteremic Agents/pharmacology , Ketones/chemistry , Sterol O-Acyltransferase/antagonists & inhibitors , Anilides/chemical synthesis , Animals , Anticholesteremic Agents/chemical synthesis , Cholesterol/blood , Intestines/enzymology , Male , Microsomes/enzymology , Rabbits , Rats , Rats, Sprague-Dawley , Structure-Activity RelationshipABSTRACT
A series of N-heteroaryl-substituted mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase both in vitro and in vivo, and to lower plasma cholesterol in a hypercholesterolemic dog model. The goal of the strategy employed was to design an inhibitor which possessed the pharmacological properties of lovastatin (1), and the physicochemical properties (increased hydrophilicity) of pravastatin (2). Two compounds 20a and 20b, were more potent than lovastatin at inhibiting cholesterol biosynthesis both in vitro and in vivo. In terms of plasma cholesterol lowering, 20a was much more efficacious than lovastatin. In addition to possessing increased biological activity, these compounds are significantly less lipophilic than lovastatin, in fact, 20b has a CLOGP value comparable to pravastatin.
Subject(s)
Anticholesteremic Agents/chemical synthesis , Cholesterol/biosynthesis , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Pyrazines/chemical synthesis , Pyrazoles/chemical synthesis , Pyridines/chemical synthesis , Animals , Anticholesteremic Agents/pharmacology , Chemical Phenomena , Chemistry, Physical , Cholesterol/blood , Dogs , Female , Lovastatin/chemistry , Lovastatin/pharmacology , Male , Molecular Structure , Pravastatin/chemistry , Pravastatin/pharmacology , Pyrazines/pharmacology , Pyrazoles/pharmacology , Pyridines/pharmacologyABSTRACT
A series of fatty acid anilides was prepared, and compounds were tested for their ability to inhibit the enzyme acyl-CoA:cholesterol acyltransferase (ACAT) in vitro and to lower plasma total cholesterol and elevate high-density lipoprotein cholesterol in cholesterol-fed rats in vivo. The compounds reported were found to fall into two subclasses with different anilide SAR. For nonbranched acyl analogues, inhibitory potency was found to be optimal with bulky 2,6-dialkyl substitution. For alpha-substituted acyl analogues, there was little dependence of in vitro potency on anilide substitution and 2,4,6-trimethoxy was uniquely preferred. Most of the potent inhibitors (IC50 less than 50 nM) were found to produce significant reductions in plasma total cholesterol in cholesterol-fed rats. Additionally, in vivo activity could be improved significantly by the introduction of alpha,alpha-disubstitution into the fatty acid portion of the molecule. A narrow group of alpha,alpha-disubstituted trimethoxyanilides, exemplified by 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide (39), was found to not only lower plasma total cholesterol (-60%) in cholesterol-fed rats but also elevate levels of high-density lipoprotein cholesterol (+94%) in this model at the screening dose of 0.05% in the diet (ca. 50 mg/kg).
Subject(s)
Cholesterol/blood , Hypolipidemic Agents/pharmacology , Sterol O-Acyltransferase/antagonists & inhibitors , Animals , Cholesterol, Dietary/administration & dosage , Male , Rabbits , Rats , Rats, Inbred Strains , Structure-Activity RelationshipABSTRACT
Structure-activity relationships are reported for a novel class of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid derivatives that displace 125I-labeled angiotensin II from a specific subset of angiotensin II (Ang II) binding sites in rat adrenal preparations. This binding site is not the Ang II receptor mediating vascular contraction or aldosterone release, but, rather, is one whose function has not yet been fully elucidated. It has been identified in a number of tissues and has a similar affinity for Ang II and its peptide analogues as does the vascular receptor. The non-peptide compounds reported here are uniquely specific in displacing Ang II at this binding site and are inactive in antagonizing Ang II at the vascular receptor or in pharmacological assays measuring vascular effects. PD 123,319 (79), one of the most potent compounds, has an IC50 of 34 nM. Certain of these compounds may have utility in the definition and study of Ang II receptor subtypes.
Subject(s)
Pyridines/chemical synthesis , Receptors, Angiotensin/drug effects , Adrenal Glands/drug effects , Adrenal Glands/metabolism , Angiotensin II/antagonists & inhibitors , Angiotensin II/metabolism , Angiotensin Receptor Antagonists , Animals , Binding Sites , Biphenyl Compounds/pharmacology , Imidazoles/pharmacology , Losartan , Pyridines/pharmacology , Rabbits , Rats , Receptors, Angiotensin/metabolism , Stereoisomerism , Structure-Activity Relationship , Tetrazoles/pharmacologyABSTRACT
Adenosine is known to exert a wide range of pharmacological effects including hypotension. This effect of adenosine suggested that modified analogues of adenosine might provide useful antihypertensive agents. Thus, we prepared a series of novel N6-benzocycloalkyladenosines and studied their receptor binding and antihypertensive activity. The structure-activity relationship study shows that the adenosine analogues having the hydrophobic phenyl moiety one carbon away from the C6-nitrogen have modest affinity and selectivity for the A1 receptor, whereas those with the phenyl moiety two carbons away from the C6-nitrogen have excellent affinity and selectivity for the A1 receptor. Many of these analogues showed excellent antihypertensive activity with a wide range of effects on heart rate. There is no direct correlation between the receptor binding affinities and antihypertensive activity; however, it is more closely associated with A1 than A2 affinity. The bradycardic effect of these agonists seems to be due to the A1 affinity. From this set, compound 3 was further evaluated in secondary antihypertensive screens. It lowered the blood pressure dose dependently with effects lasting for over 20 h following administration of a 30 mg/kg dose. Compound 3 was also effective in lowering blood pressure in a renal hypertensive rat model. Thus, appropriately modified N6-substituted adenosines represent a novel class of antihypertensive agents.
Subject(s)
Adenosine/analogs & derivatives , Antihypertensive Agents/chemistry , Cycloparaffins/chemistry , Receptors, Purinergic/metabolism , Adenosine/chemistry , Adenosine/metabolism , Adenosine/therapeutic use , Animals , Antihypertensive Agents/metabolism , Antihypertensive Agents/therapeutic use , Chemical Phenomena , Chemistry , Cycloparaffins/metabolism , Cycloparaffins/therapeutic use , Heart Rate/drug effects , Hypertension/drug therapy , Kinetics , Male , Molecular Structure , Rats , Rats, Inbred SHR , Structure-Activity RelationshipABSTRACT
A series of trans-tetrahydro-4-hydroxy-6-[2-(2,3,4,5-substituted-1H-pyrrol-1-yl) ethyl]-2H-pyran-2-ones and their dihydroxy acids were prepared and tested for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Inhibitory potency was found to increase substantially when substituents were introduced into positions three and four of the pyrrole ring. A systematic exploration of structure-activity relationships at these two positions led to the identification of a compound ((+)-33,(+)-(4R)-trans-2-(4-fluororphenyl)-5-(1-methylethyl)-N,3- diphenyl-1- [(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-4- carboxamide) with five times the inhibitory potency of the fungal metabolite compactin.
Subject(s)
Anticholesteremic Agents/chemical synthesis , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Pyrones/chemical synthesis , Pyrroles/chemical synthesis , Animals , Indicators and Reagents , Liver/enzymology , Magnetic Resonance Spectroscopy , Molecular Structure , Pyrones/chemistry , Pyrones/pharmacology , Pyrroles/chemistry , Pyrroles/pharmacology , Rats , Spectrophotometry, Infrared , Structure-Activity RelationshipSubject(s)
Anticholesteremic Agents/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Animals , Anticholesteremic Agents/chemistry , Kinetics , Male , Microsomes/enzymology , Microsomes, Liver/enzymology , Molecular Structure , Rats , Spleen/enzymology , Structure-Activity Relationship , Testis/enzymologyABSTRACT
The synthesis of a series of novel, potent angiotensin converting enzyme (ACE) inhibitors containing saturated bicyclic amino acids in place of proline is described. Octahydroindole-2-carboxylic acid, octahydroisoindole-1-carboxylic acid, and octahydro-3-oxoisoindole-1-carboxylic acid can replace proline in both sulfhydryl and non-sulfhydryl ACE inhibitors to give compounds equipotent to captopril and enalapril both in vitro and in vivo. Structure-activity relationships are discussed. Compound 11a (CI-907, indolapril) has advanced to clinical evaluation.
Subject(s)
Angiotensin-Converting Enzyme Inhibitors , Amino Acids/chemical synthesis , Amino Acids/pharmacology , Animals , Blood Pressure/drug effects , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Male , Rats , Rats, Inbred Strains , Stereoisomerism , Structure-Activity RelationshipABSTRACT
The synthesis and angiotensin converting enzyme (ACE) inhibiting activities of quinapril (CI-906, 22), its active diacid (CI-928, 33), and its dimethoxy analogue (CI-925, 25) are reported. These tetrahydro-3-isoquinolinecarboxylic acid derivatives possess equivalent in vitro potency and in vivo efficacy to enalapril. Sulfhydryl analogues with the same structural variation are also highly potent. In contrast, tetrahydro-1-isoquinolinecarboxylic acid and homologous isoindoline-1-carboxylic acid analogues show a striking divergence in potency between the two types, sulfhydryl analogues being essentially inactive, while non-sulfhydryl analogues are equipotent with the proline prototype. This is the first evidence suggesting that alternate binding modes may exist for the two major structural classes of small molecule ACE inhibitors.